We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Low-Cost, Simple-to-Use, Ultrafast Point-of-Care COVID-19 Test to Provide RT PCR Results in 8 Minutes

By LabMedica International staff writers
Posted on 09 Oct 2020
A new low-cost, simple-to-use, ultrafast point-of-care test for COVID-19 aims to provide reverse transcription polymerase chain reaction (RT PCR) results in just eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

The promising new COVID-19 rapid-testing technology platform has been developed by Rover Diagnostics (New York, NY, USA) and Columbia Engineering (New York, NY, USA). More...
Rover’s ultrafast, portable PCR technology is based on two breakthroughs in science and engineering and it meets all the conditions for successful point-of-care PCR. First, it uses microfluidic sample preparation developed by Prof. Sam Sia’s lab at Columbia University’s Dept. of Bioengineering. This technology allows Rover to eliminate expensive, complex sample prep equipment in favor of a small, disposable chip.

Secondly, the platform uses a new approach to thermal cycling that bypasses the standard Peltier device which requires 40-60 minutes for amplification. Instead of radiant heat coming from outside the vial or well, the platform use photothermal gold nanoparticles to generate heat from inside. The result is thermal cycling that is 10x faster and uses 100x less energy than is possible today. Rover aims to combine these two technologies into an easy-to-use, sample-to-answer instrument. Furthermore, Rover will integrate HIPAA-compliant cloud access to allow for instant notification and large-scale data analysis. Rover’s COVID-19 rapid-testing technology platform has been selected by the National Institutes of Health (NIH) to enter Phase 1 of the Rapid Acceleration of Diagnostics (RADx) initiative to support new COVID-19 testing technologies.

“We were determined to develop a testing platform for all kinds of viruses that is cheap, reliable, and accessible to everyone,” said Sia, an innovator in point-of-care blood tests, wearable sensors, and implantable devices. “With Rover, we can now perform thermal cycling, which is the backbone of high-performing DNA and RNA testing, several times faster.”

“We are expanding our testing of clinical samples and bringing together additional resources and expertise to finalize the design and speed to manufacturing. The NIH RADx initiative is accelerating our progress to bring the fast PCR platform to the widest possible good,” added Sia.

Related Links:
Rover Diagnostics
Columbia Engineering



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
Sample Transportation System
Tempus1800 Necto
Blood Glucose Test Strip
AutoSense Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.